Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26715018 | 0.87 | KCNH2 (0.54) | KCNH2PPARAKDM4EKMT2AMAPT | |
| SCHEMBL10255951 | 0.86 | KCNH2 (0.53) | KCNH2KDM4EKMT2AMAPTTP53 | |
| SCHEMBL26715019 | 0.84 | KCNH2 (0.51) | KCNH2KDM4EKMT2AMAPTTP53 | |
| SCHEMBL26259078 | 0.83 | PPARA (0.49) | PPARAKDM4EKMT2AMAPTTP53 | |
| SCHEMBL26695330 | 0.81 | TDP1 (0.45) | PPARAKDM4EKMT2AMAPTTP53 | |
| SCHEMBL26695337 | 0.81 | KCNH2 (0.49) | KCNH2KDM4EKMT2AMAPTTP53 | |
| SCHEMBL14785698 | 0.81 | PPARA (0.47) | PPARAKDM4EKMT2AMAPTTP53 | |
| SCHEMBL10254752 | 0.80 | TSHR (0.41) | KCNH2KDM4EKMT2AMAPTTP53 | |
| SCHEMBL10262988 | 0.80 | KDM4E (0.61) | PPARAKDM4EKMT2AMAPTTP53 | |
| SCHEMBL26695401 | 0.80 | KCNH2 (0.48) | KCNH2KMT2AMAPTTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220306627-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRUS PROTEIN 2C ACTIVITY AND FOR PREVENTING AND TREATING NON-POLIO ENTEROVIRUS INFECTION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-09-29 | — | — | US | disclosed |
| EP-2755962-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2755962-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | KCNH2 3807/4885PPARA 3560/4885KDM4E 682/4885 |
| US-20220306627-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRUS PROTEIN 2C ACTIVITY AND FOR PREVENTING AND TREATING NON-POLIO ENTEROVIRUS INFECTION | GTF3C3, VDAC3, GTF3C5 | KCNH2 846/4885PPARA 4349/4885KDM4E 3370/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | KCNH2 3807/4885PPARA 3560/4885KDM4E 682/4885 |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | GTF3C3, VDAC3, GTF3C5 | KCNH2 846/4885PPARA 4349/4885KDM4E 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.